key: cord-0964950-1uv3nmrl
authors: Lewis, S. A.; Sureshchandra, S.; Zulu, M. Z.; Doratt, B.; Pinski, A.; Curtis, M.; Jankeel, A.; Ibraim, I.; Rhoades, N.; Jiang, X.; Tifrea, D.; Zaldivar, F.; Shen, W.; Edwards, R.; Chow, D.; Cooper, D.; Amin, A.; Messaoudi, I.
title: Longitudinal analyses reveal age-specific immune correlates of COVID-19 severity
date: 2021-01-30
journal: nan
DOI: 10.1101/2021.01.25.21250189
sha: 9fb72e54051f6db1373f42ab5227a68a8ff9b19d
doc_id: 964950
cord_uid: 1uv3nmrl

Severe COVID-19 disproportionately impacts older individuals and those with comorbidities. It is estimated that approximately 80% of COVID-19 deaths are observed among individuals >65 years of age. However, the immunological underpinnings of severe COVID-19 in the aged have yet to be defined. This study captures the longitudinal immune response to SARS-CoV-2 infection in a cohort of young and aged patients with varying disease severity. Phenotypic transcriptional and functional examination of the peripheral mononuclear cells revealed age-, time, and disease severity-specific adaptations. Gene expression signatures within memory B cells suggest qualitative differences in the antibody responses in aged patients with severe disease. Examination of T cells showed profound lymphopenia, that worsened over time and correlated with lower levels of plasma cytokines important for T cell survival in aged patients with severe disease. Single cell RNA sequencing revealed augmented signatures of activation, exhaustion, cytotoxicity, and type-I interferon signaling in memory T cells and NK cells. Although hallmarks of a cytokine storm were evident in both groups, older individuals exhibited elevated levels of chemokines that mobilize inflammatory myeloid cells, notably in those who succumbed to disease. Correspondingly, we observed a re-distribution of DC and monocytes with severe disease that was accompanied by a rewiring towards a more regulatory phenotype. Several of these critical changes, such as the reduction of surface HLA-DR on myeloid cells, were reversed in young but not aged patients over time. In summary, the data presented here provide novel insights into the impact of aging on the host response to SARS-CoV2 infection.

Coronavirus disease-2019 , caused by the respiratory virus severe acute 3 respiratory syndrome coronavirus (SARS-CoV-2), has resulted in a global pandemic with over 16 4 million cases and 300,000 deaths in the U.S. alone. SARS-CoV-2 targets lung airway and alveolar 5 epithelial cells, vascular endothelial cells, and macrophages in the lung. Infection triggers a 6 vigorous innate and adaptive immune response that culminates in viral clearance or, in the case 7 of severe infections, the development of cytokine storm, acute respiratory distress syndrome 8 (ARDS), and multi-organ failure (1) . The estimated mortality rate of COVID-19 in the US is 1-2%, 9

while 40-80% of patients are thought to be asymptomatic or experience mild disease symptoms 10 (2, 3). There are numerous questions that are yet to be answered regarding the large 11 discrepancies in disease outcomes, however, it is clear that age is a significant risk factor for 12

severe . Indeed, infection fatality rate worldwide has been shown to 13 increase progressively with age (0.4% at age 55, 1.4% at age 65, 4.6% at age 75, and 15% at 14 age 85) (7). The highest proportion of patients that develop severe respiratory complications such 15 as respiratory failure, dyspnea, pneumonia, ARDS, and death are the elderly (8-13). Aging is 16 associated with immunosenescence, resulting in marked increase in susceptibility to respiratory 17 viral infections, attenuated vaccine response, and increased baseline inflammation, termed 18 inflammaging (14, 15) . It is associated with decreases in naive T and B cells, increases in effector 19 memory cells, as well as increased circulating inflammatory mediators including IL-6 and C-20 reactive protein (16). While there are clear age-associated immune adaptations in the lung that 21 could lead to a reduced ability to fight SARS-CoV-2 infection (17), age-associated frailty in blood 22 immune cells could explain paralyzed adaptive responses and poor resolution of inflammatory 23 response in aged patients with severe . However, the specific immune 24 mechanisms associated with increased severity of COVID-19 amongst the elderly and the 25 immune correlates of mild and severe disease in the aged population remains elusive. 26

There is growing evidence that severe COVID-19 is mediated by dysregulated innate and 27 adaptive immune responses. Elevated levels of interleukin (IL)-1, IL-6, IL-8, and CXCL10 in the 28 blood have been associated with more severe infection or death (19) (20) (21) (22) (23) . Furthermore, numerous 29 studies that have profiled the peripheral immune landscape during SARS-CoV-2 infection have 30 identified disruptions in distribution, activation as well as gene expression by single cell RNA 31

Sequencing of immune populations. These studies have reported complex immune dysregulation 32 in severe COVID-19, notably a pronounced decrease of HLA-DR on monocytes (21, 24, 25) , an 33 increase in non-classical CD16+ monocytes (21), and a decrease in the frequency of total 34 4 dendritic cells (DCs) (25) compared to patients with moderate/mild COVID-19 and healthy 1 controls. Additionally, it has been shown that mild disease results in increased IFN-signaling gene 2 expression, whereas severe disease leads to impaired type-I interferon responses (26) and 3 reduced ability to respond to a secondary stimulation in monocytes (27) . Studies examining NK 4 cells have reported reduced numbers of total NK cells with disease severity, but no differences 5 within subsets (28) (29) (30) . Similarly, NK cells have been shown to upregulate interferon response 6 genes but have an exhausted phenotype and reduced cytolytic activity (28, 29) . Another hallmark 7 of severe COVID-19 is lymphopenia (31) that is accompanied by increased T cell activation and 8 exhaustion (29, (32) (33) (34) (35) . 9

Data from these studies have begun to paint a picture of significant immune dysregulation 10 with COVID-19 that are potentially exacerbated in aged patients (36, 37) . Regardless, gaps in our 11 knowledge remain. Notably, comprehensive longitudinal studies that include both young and aged 12 subjects with varying disease severity (from mild to fatal) as well age-matched controls and 13 integrated transcriptional and functional analyses are needed. In this study, we carried out a 14 longitudinal phenotypic, transcriptional and functional analysis of innate and adaptive immune 15 cells from young and aged COVID-19 patients compared to age-matched healthy controls. We 16 identify age-, outcome-, and disease severity-specific alterations in the immune response to 17 SARS-CoV-2 beginning with the discovery of differential levels of circulating immune mediators 18 associated with age or survival. While we found comparable levels of antibodies in the young and 19 aged patients, changes in B cell and plasmablasts frequency and gene expression with severe 20 disease point to functional differences in humoral response. Analysis of the T cell subsets 21 revealed heightened activation and exhaustion states with severe disease and an age-associated 22 exacerbation of interferon and cytotoxicity signaling. Functionally, this led to immune paralysis in 23 the T cell response. Similarly, the NK cell subsets showed discrepancies between mild and severe 24 infection states where strong interferon induction dominated the mild response, but increased 25 exhaustion and cytotoxicity markers were associated with more severe disease. Finally, severe 26 COVID-19 resulted in a functional rewiring of monocytes and DC towards a more regulatory 27 phenotype where NF-κB mediated responses were diminished. Broadly, a robust interferon gene 28 signature was detected in individuals with mild disease but appeared late in those with severe 29 disease. The findings presented here are critical and necessary for our understanding of anti-viral 30 responses in the elderly and necessary for our ongoing fight against the COVID-19 pandemic. 31 32 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 22

Raw reads were aligned and quantified using the Cell Ranger Single-Cell Software Suite with 25 Feature Barcode addition (version 4.0, 10X Genomics) against the GRCh38 human reference 26 genome using the STAR aligner. Downstream processing of aligned reads was performed using 27 Seurat (version 4.0). Droplets with ambient RNA (cells fewer than 200 detected genes) and dying 28 cells (cells with more than 25% total mitochondrial gene expression) were excluded during initial 29 QC. Data objects from all groups were integrated using Seurat (version 3.2.2) (38) using the 30 healthy, young donor samples as the reference. Data normalization and variance stabilization 31 was performed on the integrated object using the SCTransform function where a regularized 32 negative binomial regression corrected for differential effects of mitochondrial gene expression 33 levels. The HTODemux function was then used to demultiplex donors and further to identify 34 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2021. ; 9 doublets, which were then removed from the analysis. Dimension reduction was performed using 1

RunPCA function to obtain the first 30 principal components followed by clustering using the 2 FindClusters function in Seurat. Clusters were visualized using the UMAP algorithm as 3 implemented by Seurat's runUMAP function. Cell types were assigned to individual clusters using 4

FindMarkers function with a fold change cutoff of at least 0.4 and using a known catalog of well-5 characterized scRNA markers for human PBMC (39). Clusters from three major cell types (T and  6 NK cells, myeloid cells, B cells) were further subsetted from the total cells and re-clustered to 7 identify minor subsets within those groups. List of cluster specific markers identified from this 8 study are cataloged in Supp Table 2.  9 10 Pseudo-temporal analysis 11

Pseudotime trajectory of CD4 and CD8 T cells and monocytes was reconstructed using Slingshot 12 (40). The analysis was performed on each of these subsets individually with Treg and MAIT cells 13 excluded from T cell analysis due to unique developmental origins. For each set of cells, the 14 UMAP dimensional reduction performed in Seurat was used as the input for Slingshot. For 15 calculation of the lineages and pseudotime in the T cell subsets, the naive clusters were set as 16 the root state. In the monocytes, MS1 was set as the root state. 17 18

Differential expression analysis was performed using MAST using default settings in Seurat. All 20 disease comparisons were performed relative to healthy donors from corresponding age groups. 21

Only statistically significant genes (Fold change cutoff ≥ 1.5; adjusted p-value ≤ 0.05) were 22 included in downstream analysis. 23

For gene scoring analysis, we compared gene signatures and pathways from KEGG 26 (https://www.genome.jp/kegg/pathway.html) (Supp Table 3 Over representative gene ontologies were identified using 1-way, 2-way, 4-way and 8-way 34 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. To comprehensively assess the peripheral immune response to SARS-CoV-2 infection with 5 age, we performed a combination of immunological, single cell transcriptomic, and functional 6 assays ( Figure 1A ) using blood samples obtained from 49 healthy donors (37 young and 12 7 aged), 20 mild/ asymptomatic COVID-19 patients (10 young and 10 aged), and 47 severely 8 infected COVID-19 patients (35 young and 12 aged) with longitudinal sampling based on days 9 post symptom (DPS) onset (median ~10 DPS). Each group contained young (<60 years, median 10 age 42.5 years) and aged patients (≥60 years, median age 69) including six patients (2 young 11 and 4 aged) who succumbed to infection (Supp. Table 1 ). Levels of circulating immune mediators 12

were measured using a Luminex assay (Supp Figure 1A) . While several soluble factors 13 increased comparably with both mild and severe COVID-19 (IFNγ, IFN⍺, TRAIL, TNF⍺, IL-12, IL-14 33, IL-15, IL-13, and G-CSF), others increased to a greater extent with severe infection 15 MIP-1⍺, MIP-1β, CD40L, Fractalkine, GRO⍺, GROβ, EGF, Flt-3, IFNβ, IL-1β, IL-1RA, IL-2, TGF⍺, 16 and PDGF-AA) (Supp Figure 1A) . Levels of PDL-1, Granzyme B, RANTES, and VEGF were 17 significantly lower in aged patients with severe disease compared to their younger counterparts, 18 while levels of IP-10, GM-CSF, IL-10, and TRAIL were significantly elevated (Supp Figure 1A  19 and Supp. Figure 1B) . 20

Linear regression analysis of soluble mediators over the course of infection in severe patients 21 revealed that levels of G-CSF, Flt-3L, EGF, CD40L only correlated positively with days post 22 symptom onset (DPS) in young patients ( Figure 1B) . Interestingly, levels of IL-10 and IFN⍺ 23 negatively correlated with DPS in patients that survived regardless of their age, but not in patients 24 who succumbed in infection ( Figure 1C) . Contrarily, levels of MIP-3⍺, MIP-1⍺, IFNγ, and IL-1RA 25 were significantly positively correlated with DPS only in patients that succumbed to infection 26 ( Figure 1D ). We used supervised random forest modeling to determine factors predictive of 27 disease severity independent of age (Supp. Figures 1C-F) . At 1-5 DPS, IL-17A plasma levels 28

were the strongest predictor of disease severity and positively associated with mild/moderate 29 disease (Supp. Figures 1C,D) . Later in the disease course (>10 DPS) levels of growth factors 30 TGF-⍺, VEGF, and PDGF-AB/BB were the strongest predictors of disease severity and positively 31 associated with worse outcomes (Supp. Figures 1E,F) . 32

To assess the impact of age and COVID-19 disease severity on peripheral immune 33 adaptations, we profiled peripheral blood mononuclear cells (PBMC) from each patient by flow 34 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2021. ; cytometry. Analysis of major populations in the blood including B cells, T cells, NK cells, dendritic 1 cells (DC), and monocytes identified significant phenotypic differences, particularly with severe 2 disease and age ( Figure 1E) . Specifically, decreased percentages of naive B cells and a 3 concomitant increase in memory B cell fractions was observed in aged patients with severe 4 disease compared to healthy donors. Increased frequencies of central memory CD8 T cells (TCM) 5 were detected in patients with mild disease, especially the aged, while no changes were detected 6 in the CD4 T cell subsets. Moreover, severe disease was associated with a linear drop in T cell 7 frequencies across DPS in aged patients (Figure 1F,G) . Frequencies of DC subsets decreased 8 significantly in both aged and young patients regardless of disease severity, whereas monocytosis 9 was observed only in young patients with severe COVID-19 ( Figure 1E) . 10

To further probe the peripheral immune response during COVID-19 infection, PBMC from 16 11 patients (Young Mild=4; Young Severe=4; Aged Mild=4; Aged Severe=4) and 8 healthy donors 12 (Young HD=4; Aged HD=4) were profiled by scRNA-Seq using the 10X Genomics platform. For 13 patients with severe disease, we profiled PBMC at three time points over the course of acute 14 infection (Supp. Figure 2A ). An average of 2,082 cells were sequenced per patient and time point 15 for a total of 92,648 cells (Supp. Figure 2B ). Dimensional reduction using Uniform Manifold 16

Approximation and Projection (UMAP) revealed distinct clustering into the major peripheral 17 immune subsets ( Figure 1H ). Clusters were annotated based on highly expressed marker genes 18 using Seurat's FindMarkers function (Supp. Figure 2C and Supp. Table 2 ). While we did not 19 identify significant changes in the frequency of major populations in this subset of samples, we 20 were able to capture shifts in minor populations including plasmablasts, NKT cells, and DC with 21 age and disease severity (Supp. Figure 2D) . 22

Reduced activation of memory B cell subsets in aged patients with severe disease but no 24 differences in antibody levels 25

To assess the impact of disease severity and age on humoral responses to SARS-CoV-2 26 infection, we reclustered the B cells and plasmablasts and identified five subsets based on 27 expression of key B cell markers (Figure 2A and Supp. Figure 3A) . Modest increases in 28

proportions of plasmablasts were observed with disease but were more prominent in younger 29 patients with mild disease (Supp. Figure 2D and Supp. Figure B) . Differential expression 30 analysis within each group relative to age-matched healthy donors revealed increased expression 31 of plasma cell genes MZB1, CD38, and SDC1 in severe disease in plasmablasts regardless of 32 age while expression of immunoglobulin heavy chain genes IGHG3 and IGHM was only increased 33 in young patients with severe disease (Figure 2B ). Mild disease was associated with upregulation 34 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2021.

13 of genes associated with B cell commitment to plasma cells and antibody production (IRF4, 1 XBP1). Interestingly, expression of SSR4, important for B cell effector function, was increased 2 with infection in young patients but decreased in aged patients ( Figure 2B) . 3

Despite these gene expression differences, levels of IgG and IgM specific to nucleocapsid protein 4 (NP) and receptor-binding domain (RBD) were comparable in young and aged patients (Supp. 5 Figure 3C ). Independent of age, antibodies against NP showed a stronger positive correlation 6 with DPS compared to antibodies against RBD ( Figure 2C ). Poor induction of NP-specific IgM 7 levels was detected in patients who succumbed to COVID-19. Additionally, levels of NP-and 8 RBD-specific IgG were lower in aged patients who succumbed to disease during DPS 1-5 (Supp. 9 Figure 3D ). 10 We next identified disease and age-specific changes in frequency and gene expression within 11 memory B cell subsets. Independent of age, frequency of total and proliferating terminally 12 differentiated B cells was increased in patients with severe disease, while that of total and 13 proliferating marginal zone-like (MZ) B cells was increased only in patients with mild disease 14 ( Figure 2D ). However, while severe disease was associated with induction of genes associated 15 with B cell activation (CD40, TRAF4, NFKB1/2 and REL), these changes were less pronounced 16 in aged subjects ( Figure 2E) . Interestingly, expression of heavy chain gene IGHG3 increased 17 with infection in young patients but decreased in aged patients. Finally, IFI44L was increased to 18 a greater extent with mild disease than severe disease ( Figure 2E) . (expressing high CD69, S100A4), and CD4 TEMRA (expressing low CCR7 but high PTPRC and 29 RORA) ( Figure 3A and Supp. Figure 4A ). Pseudotime analysis of CD4 T cells placed cells along 30 a trajectory arising from naive CD4 followed by TCM CD4 and ending in TEM (Supp. Figure 4B) . 31

While the frequencies of CD4 TEM did not vary significantly with mild or severe disease, 32 significant transcriptional changes were observed with severe disease relative to healthy donors 33 only in the aged subjects ( Figure 3B) . Specifically, up-regulation of pathways associated with 34 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2021.

lymphocyte activation (CD3E, IL2RA, IL7R), response to type-I interferons (IFI6, IRF1), and 1 positive regulation of cell death (FAS) ( Figure 3B ), were observed in T cells from aged patients 2 with severe disease. Interestingly, genes associated with antiviral immunity (ISG15, ISG20, MX1, 3 TRIM8) were up-regulated predominantly in aged patients with severe disease ( Figure 3B ). 4

Severe COVID-19 was associated with enrichment of CD4 TEMRA subset, most notably in young 5 patients (Supp. Figure 4C) . Moreover, this subset was transcriptionally dysregulated with severe 6 disease in aged patients compared to their control counterparts ( Figure 3C ). Specifically, 7 expression of genes associated with ATP metabolism, calcium signaling and response to hypoxia 8 (including cytotoxic molecules such as GZMA, GZMB, and KLRD1) was decreased in aged 9 patients with mild disease and increased in aged patients with severe disease ( Figure 3D ). Genes 10 that were uniquely down-regulated with severe disease in aged patients enriched to gene 11 ontology (GO) terms associated with antiviral immunity and type-I IFN signaling (Supp. Figure  12 4D). A consistent theme across in both TEM and TEMRA clusters was up-regulation of genes 13 that map to cell death signaling GO terms with severe disease, confirmed by increased scoring 14 of Fas signaling module in memory CD4 T cells with severe COVID-19, especially aged patients 15 (Supp. Figure 4E and Supp. Table 3) . Figure 4A ). Pseudotime 24 analysis placed the CD8 T cells along a trajectory starting from naive CD8, antiviral CD8, activated 25 CD8, and terminating in cytotoxic CD8 subsets (Supp. Figure 4F ). The phenotypes of these 26 subsets were confirmed using module scoring -CD8 GZMH high and expressed the highest levels 27 of cytotoxicity genes; CD8 CD69 high the highest cytokine score; and the CD8 IFN cluster the 28 highest interferon module scores (Supp. Figure 4G ). We observed a modest decrease in naive 29 CD8 T cells in the young group with COVID-19 (Supp. Figure 4H ) and a modest increase in CD8 30 IFN cluster in aged patients with mild disease (Supp. Figure 4I ). No differences in the frequencies 31 of CD8 GZMK high or GZMH high clusters were observed with mild/severe disease(Supp Figure  32 4J,K). However, we observed a significant reduction in CD8 GZMK high cells in aged patients who 33 succumbed to disease compared to those who did not (Supp Figure 4K) . Comparisons of 34 COVID-19 associated differentially expressed genes in memory CD8 T cells revealed up-1 regulation of pro-survival (BCL2) and antiviral factors (OAS3, TXNIP) with mild disease and 2 enrichment of factors associated with the tissue resident CD8 T cell development program 3 (RUNX3, VIM, TGFB1) in severe patients ( Figure 3E ). More importantly, while CD8 T cells from 4 both young and aged severe COVID-19 patients expressed elevated levels of chemokines 5 (CCL4L2, XCL2) and cytotoxic molecules (PRF1, GZMB, KLRD1) ( Figure 3E ), the overall 6 cytotoxicity scores in GZMK high clusters were significantly higher in aged patients ( Figure 3F ). As 7 observed in the CD4 TEM cluster, severe disease was associated with signatures of heightened 8 CD8 T cell activation (CD3D and CD8A) ( Figure 3E ). Finally, our analyses revealed significant 9 up-regulation of interferon signaling in all CD8 T cell clusters with mild disease in both young and 10 aged subjects (Supp. Figure 5A ), being significantly higher in young mild relative to aged mild 11 (p< 0.0001). However, severe disease in the aged was associated with elevated interferon 12 signaling scores relative to severe young (p<0.0001), peaking at days 18-19 DPS (Supp. Figures  13   5A,B) . 14 15

Single cell RNA-Seq analysis revealed enrichment of proliferating T cell subsets with severe 17 COVID-19 in both young and aged patients (Supp. Figure 5C ). We confirmed these observations 18 in a larger set of samples by measuring Ki67 expressing using flow cytometry. Our analysis 19 revealed that proliferating T cells in CD4 and CD8 subsets were prominent within central memory 20 ( Figure 3G ) and effector memory ( Figure 3H ) compartments respectively. This induction of 21 proliferating CD4 and CD8 T cells was significantly reduced in aged severe patients compared to 22 young counterparts ( Figure 3G ,H). In line with this defect, we observed a progressive increase in 23 T cell maintenance factors IL-2 (r 2 =0.39, p<0.0001) and IL-7 (r 2 =0.35; p<0.001) only in young 24 patients with severe disease ( Figure 3I ). Furthermore, a sharp decline in IL-2 signaling signatures 25 was detected in memory CD4 T cells from aged subjects with severe disease only (r 2 =-0.28) 26 (Supp. Figure 5D ). Finally, we observed modest reduction in frequencies of both proliferating T 27 cells and regulatory T cells in aged patients who succumbed to the disease (Supp. Figure 5C) . 28

Next, we tested if severe SARS-CoV-2 infection alters the ability of T cells to respond to 29 SARS-CoV-2 peptides or polyclonal stimulation (nHD=3; convalescent=4; nsevere=9). While T cells 30 from convalescent patients secreted significantly higher levels of IFN relative to healthy donors 31 in response to several of the viral peptide pools, these responses were significantly attenuated 32 with severe disease ( Figure 3J ). We also noted weaker T cell responses to polyclonal stimulation 33 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2021.

in patients with severe disease relative to healthy donors (p<0.01) and an independent group of 1 convalescent health care workers (sero-positive) (p<0.001) ( Figure 3J ). 2 3

with severe COVID-19 5

Given their critical role in antiviral immunity during acute infection, we next examined the 6 impact of COVID-19 disease severity and age on NK cell phenotypes. The two major populations 7 of NK cells were identified by scRNA-Seq (NK CD16 hi , NK CD56 hi ) based on expression of 8 FCGR3A and NCAM1 (Figure 3A , Supp. Figure 6A) . We also identified a cluster of cells 9 expressing NK and CD8 T cell markers (CD8A, PLCG2) which we call CD8/NK T cells. The 10 percentage of CD8/NK T cells increased significantly in young patients and modestly in aged 11 patients with severe disease, but negatively correlated with DPS (Supp. Figure 6B ,C). No 12 differences in major NK cell populations were detected with mild/severe disease in young or aged 13 subjects, either by flow cytometry or scRNA-Seq (Supp. Figure 6D ). However, the frequency of 14 NK cells expressing activation marker KLRG1 and/or terminal differentiation marker CD57 was 15 decreased in young patients with severe disease but increased in aged patients with severe 16 disease ( Figure 4A) . Additionally, NK cell exhaustion module scores from the CD56 hi cluster 17 determined from the scRNA-Seq analysis were increased with severe disease ( Figure 4B ). 18

Moreover, induction of a robust cytotoxic program with severe disease was evident from 19 significant increase in CD56++ GranzymeB+ (flow cytometry) and expression of PRF1 and IFNG 20 (single cell RNA), which were less pronounced in severe aged ( Figure 4C,D) . 21

Even though frequencies of CD16++ NK cells did not change with disease severity/age (Supp. 22 Figure 6D ), we observed significant changes in their transcriptional program with COVID-19. 23 DEG from each disease group compared to their age-matched healthy donors enriched to GO 24 processes associated with leukocyte activation, cell death, and response to virus ( Figure 4E ). 25

Interestingly, the same pathways that were being upregulated with severe disease in the aged 26 patients including lymphocyte activation and leukocyte activation in immune response were 27 strongly downregulated with mild infection in the young patients. Indeed, genes involved in cell 28 migration (LGALS3 and CCL5) and activation (HLA-DRB1) were highly upregulated with severe 29 disease in aged patients ( Figure 4F ). On the other hand, antiviral signatures including numerous 30 interferon stimulated genes (ex. ISG20, IFIT3, IFITM1) as well as B2M, IRF7, and STAT1 were 31 upregulated with mild disease ( Figure 4F ). Finally, a number of molecules associated with 32 cytokine signaling (TNFSF4, TNFRSF18, STAT3, TNF, MAP3K8, RELA) and a number of 33 cytokines and chemokines and their receptors (CXCR4, IFNGR1, IL21R, IL4R) were upregulated 34 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2021. ; with severe disease but to a less extent in aged patients ( Figure 4F ). This trend was confirmed 1 from functional module scoring which showed dampened cytokine and chemokine receptor 2 signaling scores with severe disease in the aged (p=0.09) (Supp. Figure 6E ). Module scoring 3 revealed increased expression of interferon signatures in both NK subsets with mild disease, but 4 exacerbation of this signal with age in both CD56 hi (p<0.05) and CD16 hi (p<0.0001) subsets 5 (Supp. Figure 6F ). Further examination of the interferon response module in the severe patients 6 across DPS showed this increase occurred only at later infection timepoints irrespective of age 7 (Supp. Figure 6G) . 8 9

Our initial PBMC analysis showed increased monocyte frequency in young patients only 12 ( Figure 1E ). However, within monocyte subsets, we detected increases in non-classical 13 monocytes in both young and aged subjects while frequencies of classical monocytes were 14 significantly reduced in the aged patients with severe disease ( Figure 5A ). In contrast, 15

proportions of both DC subsets -pDCs and mDCs was reduced in both young and aged COVID-16 19 patients regardless of disease severity ( Figure 1E and Figure 5B ). Additionally, expression 17 of MHC Class II molecule HLA-DR and activation marker CD86 were broadly decreased with 18 COVID-19, although the decrease was more significant with severe disease (Supp. Figure 7A,B) . Figure 7C,D) . Scores of the MHC Class II module were significantly 25 reduced in classical (mild and severe disease) and non-classical (severe disease) monocytes in 26 both age groups (Supp. Figure 7E) . However, severe age was associated with further reduction 27 in MHC Class II module scores in classical monocytes (Supp. Figure 7E) . We also detected 28 minor redistribution of monocyte subsets with disease severity and age. Specifically, the MS1 29 cluster (expressing high levels of CXCL8 and IL1B) (Supp. Figure 7D ) decreased in young 30 patients, while the MS4 cluster (expressing antiviral genes) (Supp. Figure 7D ) increased in 31 patients with mild disease (Supp. Figure 7F,G) . Trajectory analysis revealed three unique 32 lineages within the monocyte subsets ( Figure 5D ). Lineage 1 started in the MS1 cluster and 33 ended with the non-classical monocytes. Lineage 3 moved through the viral cluster, upregulating 34 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2021. ;

IFI30 and IFITM2, before returning back to MS1. Interestingly, lineage 2 which moved from MS1 1 towards MS2, was driven almost exclusively by cells from aged patients, and was defined by 2 increased expression of regulatory markers CD163 and F13A1 ( Figure 5D ). Skewing of 3 monocytes towards a regulatory phenotype with severe disease was confirmed by increased 4 surface expression of CD163 as well as adhesion molecule CD62L on monocytes from patients 5 with severe COVID-19 ( Figure 5E ). Additionally, surface expression of CX3CR1 and CD11b was 6 downregulated while that of CCR5 and CD64 upregulated with severe disease (Supp. Figure  7   7H ). Regression analysis further indicated that expression of CCR5 and CD64 progressively 8 decreased with disease progression (Supp. Figure 7H) . 9

Differential gene expression analysis within classical monocytes revealed significant 10 enrichment to GO terms response to virus and response to IFN pathways in all patients, that was 11 most significant in monocytes from aged subjects with mild disease (Figures 5F). A handful of 12

ISGs were up-regulated more significantly in young patients with mild disease (ISG15, IFITM1, 13 IRF1) ( Figure 5G) . However, the overall interferon signaling signature was heightened in aged 14 patients with severe disease (Figure 6A ). Similar trends were observed in nonclassical 15 monocytes (Supp. Figure 8A) . Interestingly, within classical monocytes expression of alarmin 16 molecules (S100A8, S100A9, S100A12) was increased while that of chemokines was decreased 17 (CXCL8, CCL3, CCL4, CXCL2, CXCL3) with severe disease ( Figure 5G) . Moreover, the 18 magnitude of that change was higher in the aged ( Figure 5G) . Finally, significant changes in 19 expression of genes associated with wounding response, myeloid cell activation, and 20 hematopoiesis were observed in non-classical monocytes with both mild and severe disease in 21 the aged subjects (Supp. Figure 8A ). DEG analysis in the mDC subset revealed significantly 22 increased expression of IFN-responsive genes ISG20, MX1, STAT1, and IFI44L with disease in 23 aged patients (Supp. Figure 8B) . RIGI signaling was also increased in the mDC population from 24 the aged patients with only a modest increase in young patients (Supp. Figure 8C) . Finally, 25 module scoring of all the myeloid subsets revealed a decrease in NF-κB signaling with COVID-26 19 (mild and severe disease in classical monocytes; mild disease in nonclassical monocytes) 27 ( Figure 6A) . 28

To analyze the functional capacity of myeloid cells to respond to a secondary infection, we 29 stimulated total PBMC from a subset of our patient cohort with either a viral or bacterial agonist 30 cocktail and measured the production of IL-6, TNF⍺, and IFN⍺ in monocytes and DC ( Figure  31 6B)(nHD=4; nsevere=15). In response to either bacterial or viral agonists, a lower percentage of both 32 monocytes and DC in severe patients produced IL-6 and TNF⍺, regardless of age ( Figure 6C) . 33

Stratifying the IFN⍺ responses across DPS revealed that in severe patients, there was a positive 34 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2021. ; correlation of interferon production with DPS ( Figure 6D) . These data suggest that severe 1 COVID-19 leads to a re-wiring of the inflammatory response pathways in myeloid cells with 2 implications for response to secondary infections. 3 4 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2021. ;

The clinical presentation of COVID-19 is highly heterogeneous, influenced by host factors such 2 as age, sex, BMI, and underlying medical conditions, notably diabetes, hypertension, and 3 cardiovascular disease. Advanced age is a major driver of severe disease with 78.2% of deaths 4 occurring in people ≥65 years of age (43) . This increased vulnerability of older individuals to 5 respiratory viral infections is mediated by age-associated deterioration of immune function 6 (immunosenescence) and baseline inflammation (inflammaging), which can exacerbate host 7 response to . While recent studies have shed light on host response to mild and 8 severe COVID-19, most of these studies used mixed cohorts; thus, the immune correlates of the 9 disease in aged populations remain unclear. To address this question, we profiled the 10 inflammatory environment using luminex and the immune landscape using flow cytometry and 11 single cell RNA-sequencing in blood samples from young and aged patients with mild and severe 12 COVID-19 and compared these measurements to those obtained in age-matched healthy donors. 13

Our analysis revealed that independent of disease severity, COVID-19 was associated with a 14 significant shift in plasma inflammatory factors, including elevated Th1 (IFN , TNFɑ, IL-12) and 15

Th2 cytokines (IL-13, G-CSF). Severe disease, however, was associated with a more prominent 16 elevation of pro-inflammatory cytokines (IL-1β, IL-2, IL-7) and chemokines (MCP-1, MIP-1ɑ, MIP-17 1β, CX3CL1, GRO-ɑ, and GRO-β), and growth factors (TGF-ɑ, PDGF-AA) compared to both 18 healthy donors and those with mild disease. These observations highlight a cytokine storm that 19 is exacerbated with severe disease, as previously reported (21, 23) . Importantly, our analysis 20 revealed that older subjects with severe disease showed significantly higher induction of GM-21 CSF, IP-10, and IL-10 but lower levels of PD-L1, VEGF, and RANTES compared to their younger subjects with severe COVID-19, particularly in non-survivors. Our analysis also indicate that lower 31 levels of IL-17 during the first 5 DPS was associated with poor prognosis (ICU 32 admission/intubation and death). This observation differs from recent reports that high levels of 33 IL-17 (21) and Th17 cells (48) is correlated with immunopathology of severe COVID-19 and the 34 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2021. ;

proposed use of IL-17 blockade as a therapeutic avenue to limit acute lung injury (49). This 1 discrepancy highlights the need for careful evaluation of the timing for administering immune 2 modulators in the context of We next utilized a combination of flow cytometry, single cell RNA sequencing and functional 4 assays to better understand age-specific immunological changes with mild and severe COVID-5 19. As previously reported, substantial induction of plasma B cells was observed with mild disease 6 (29, 50-52), though less prominent in aged individuals. Furthermore, gene signatures associated 7 with commitment to plasma cells were more robust with mild disease. Interestingly, while mild 8 disease was associated with accumulation and proliferation of marginal zone B cells, severe 9 disease was associated with accumulation of IgD-CD27-memory B cells, which have been linked 10 to severe outcomes following COVID-19 (50). Finally, transcriptional signatures associated with 11 B cell activation and NF-κB signaling were dampened in aged subjects with severe COVID-19. 12

Coupled with lower levels of plasma CD40LG in aged subjects with severe disease, these 13 observations suggest weak T follicular helper cell responses in the aged. Surprisingly, plasma 14 antibody levels (IgG or IgM) against SARS-CoV-2 proteins RBD and NP increased similarly with 15 DPS in young, aged, and deceased subjects. However, our analysis did not evaluate age-related 16 differences in avidity, neutralization, and effector functions of antibodies, which should be a focus 17 of future studies. In addition to loss of T cells, and suppressed proliferation, there is mounting evidence pointing at 33 T cell dysfunction/exhaustion with severe 48, 54, 55) 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2021. ; https://doi.org/10.1101/2021.01.25.21250189 doi: medRxiv preprint 22 with COVID-19 have been described to be functionally exhausted, expressing elevated levels of 1 54) . Here, we report gene expression differences in memory CD4 and CD8 T cells 2 indicative of increased T cell activation signatures with severe COVID-19 in the aged subjects. 3

Given previous reports of elevated HLA-DR+ T cells with severe disease (50, 54), we conclude 4 that these observations are suggestive of broad T cell activation, which are exacerbated with age. 5

Furthermore, this hyperactivation of T cells could also explain the depletion of T cells, which is 6 more significant in aged subjects. Functional exhaustion of T cells with severe COVID-19 is further 7 evident from lack of IFN production in response to SARS-CoV-2 peptide pools as well as 8 polyclonal stimulation. These findings are consistent with reduced function of CD4 T cells in acute 9 phase of infection following PMA/ionomycin stimulation (56), but are inconsistent with reports of 10 comparable IFN CD8 responses or even IFN , TNFɑ, and IL-2 CD4 responses following 11 CD3/CD28 stimulation (48, 54). These discrepancies are likely due to differences in the age of 12 the patient, disease severity and the length of stimulation. 13

Gene expression changes reported here also suggest that CD8 T cells from patients with severe 14 disease exhibit increased cytotoxicity (based on increased expression of GZMB, PRF1, XCL1, 15 XCL2) and NK cell markers (KLRD1), as previously reported using flow cytometry (25). 16 Importantly, cytotoxicity module scores within CD8 clusters identified by scRNA Seq are 17 significantly higher in aged subjects. However, within the aged cohort with severe disease, 18 patients who succumbed to the disease had attenuated frequencies of GZMK high CD8 T cells 19 relative to patients who survived. This observation is line with reports of reduced cytotoxic 20 potential in EM/TEMRA CD8 T cells from severe patients older than 80 yrs of age (36). 21

Enhanced cytotoxicity with severe disease is also evident by increased frequencies of GRZMB+ 22 CD56+ NK cells with severe disease. We also report increased frequencies of KLRG1+ NK cells 23 in aged subjects with severe COVID-19 (57) relative to age-matched HD and young subjects with 24 severe COVID-19. Enhanced activation and functional exhaustion of NK cells have recently been 25 described (30, 36, 57) in the context of severe COVID-19. Our data suggests that this 26 dysregulated state is further exacerbated in aged subjects, with lower frequencies of GranzymeB+ 27 NK cells and reduced expression of IFNG and PRF gene in the more cytotoxic CD56++ NK cells. 28

In line with these observations, we observed significantly lower levels of circulating Granzyme B 29 in aged patients with severe disease. 30

Our data show an increase in non-classical monocytes in both young and aged patients with 31 severe disease; however, an increased prevalence of classical monocytes is only evident in 32 young subjects. Consistent with previous observations (29), we report attenuated induction of 33 cytokine/chemokine transcripts in monocytes with severe disease. Surface expression of CCR5, 34 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2021. ; a target for limiting cytokine storms in COVID-19 (58) is significantly elevated early in disease, 1 but wanes with disease progression. We also report an up-regulation of surface CD64 expression, 2 which has also been linked to cytokine release (50, 58), early that wanes with disease 3 progression. Expression of calprotectin (S100A8, S100A9 complex) has been proposed as a 4 factor discriminating mild vs. severe disease (59). Both S100A8 and S100A9 were further 5 elevated in monocytes from aged patients with severe disease. Taken together, our studies 6 suggest that while circulating monocytes are not the primary source of cytokine storm in blood, 7 severe COVID-19 is associated with a heightened state of inflammatory signaling in monocytes 8 that is exacerbated in aged subjects. In contrast to monocytes, a significant drop in both myeloid 9 and plasmacytoid dendritic cells in blood is observed with severe disease regardless of age (29, 10 50). This reduction could be due to recruitment to the lung. Significant induction of factors that 11 regulate hematopoiesis (Flt-3L, G-CSF, IL-33) was only observed in young patients suggesting 12 robust mobilization of myeloid cells in the young group. DCs from patients with severe disease also responded poorly to bacterial TLR agonists. 22

Functional impairment of DCs with acute SARS-CoV-2 infection has been recently described (56). 23

These findings suggest that severe disease could potentially lead to innate immune paralysis 24 leaving the host vulnerable to secondary bacterial infections as recently described (61). In 25 contrast to the dampened response following stimulation with bacterial antigens, we report 26 elevated RIG-I signaling module with severe disease, particularly in myeloid DCs in aged 27 subjects. In line with the higher IFN module score, stimulation of both monocytes and DCs with 28 viral agonists targeting TLRs 7/8/9 resulted in higher interferon signal over the course of infection, 29 suggesting innate immune signaling preferentially geared towards antiviral signaling. 30

Recent studies have highlighted both impairment of type I interferon activity and inflammatory 31 responses with severe COVID-19 (26). Our data suggest systemic elevation of both type I and II 32 interferon in the periphery for all groups. However, cellular expression of interferon signatures 33 varied by disease severity, immune cell type, age, and DPS. Specifically, we observed consistent 34 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2021. ; upregulation of interferon signaling in monocytes, B cells, and NK cells with mild disease and to 1 a lesser degree with severe disease. Within CD8 T cells, while both mild and severe disease 2 triggers an enhanced interferon response, severe disease activates a more robust cytotoxic 3

disease revealed a late induction of interferon signatures (18-20 DPS), coinciding with 5 progressive decline in plasma IL-10 levels in surviving patients. Mild disease, however, was 6 characterized by up-regulation of feedback regulators such as IFI44L (in B cells, DCs, monocytes, 7 NK cells) (62), suggesting mechanisms of efficient control of host innate responses in addition to 8 control of viral replication with mild COVID-19. In contrast, within CD4 T cells and DCs, we 9 observe stronger ISG signaling with severe disease, particularly in the aged subjects, potentially 10 due to delayed viral clearance. Exaggerated innate immunity in the lung, impaired antigen 11 presentation, and lymphopenia are hallmarks of other respiratory viral infections such as influenza 12 and RSV in the aged (17). Our analysis extends these observations and confirms the impairment 13 of innate and adaptive immune responses in blood following severe COVID-19 in aged patients. 14 15

We acknowledge several limitations in our study design and implementation. Firstly, we analyzed 16 immune parameters by days post symptom onset, which being self-reported can be rather 17 inaccurate and arbitrary. Secondly, we broadly defined patients with mild disease as ones with a 18 positive PCR test with either no symptoms associated with COVID-19 or a mild disease not 19 requiring extensive (>3 days) hospital stay. Lack of longitudinal samples from patients from this 20 category prevented us from modeling disease dynamics with varied severity. Thirdly, given the 21 nature of this pandemic, there are some biases in patient and healthy donor cohorts. For example, 22 healthy donor subjects were predominantly female (68% in young; 58% in aged) whereas a 23 significant number of patients with severe disease were Hispanic (69% in young; 75% in aged). 24

Additionally, patients in severe categories presented with a wide array of underlying conditions 25 that might have played a role in disease severity/outcome. A significant number of patients were 26 treated with remdesivir, however, there is limited evidence suggesting its role in either immune 27 activation or suppression in blood. Due to limited statistical power, we pooled patients with severe 28 disease at any DPS timepoint into one category for initial analysis before regressing the data with 29 time. Future studies will stratify young and aged patients by clinical scores to identify innate 30 immune correlates of disease severity and identify determinants of disease resolution and survival 31 in patients with severe COVID-19. More importantly, addressing the impact of age on qualitative 32 differences in humoral responses and long-term durability of T cell responses to SARS-CoV-2 33 would be critical in designing vaccine and therapeutic strategies in the aged population. 34 35 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2021. ; represents the average expression and the size represents the percentage of cells expressing 33 that gene. *=significant compared to healthy donors, += significant compared to mild patients, 34

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2021. ; #=significant difference between Aged Mild/Severe and Young Mild/Severe groups where 1 */+/#=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2021. ; plot representing functional enrichment of DEG in CD16 high (FCGR3A high ) NK cells from aged and 1 young subjects with mild and severe COVID-19. Color and size of the bubble represents statistical 2 significance and number of genes respectively. (F) Clustered heatmap comparing normalized 3 expression of genes enriching to GO term "lymphocyte activation" from CD16 high NK subset 4 obtained from patients with mild and severe COVID-19. Colors represent scaled gene expression 5 ranging from blue (low) to red (high). Select genes are highlighted. *=significant compared to 6 healthy donors, += significant compared to mild patients, #=significant difference between Aged 7

Mild/Severe and Young Mild/Severe groups where */+/#=p<0.05, **=p<0.01, ***=p<0.001, 8 ****=p<0.0001. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2021. ; bacterial agonists (Pam3CSK4, LPS, and FSL-1) and viral agonists (ssRNA, Imiquimod, 1 ODN2216) separately for 8 hours. Cytokine responses (TNFɑ, IL-6, and IFNɑ) were measured 2 using intracellular staining followed by flow cytometry. (C) Dot plots comparing frequencies of 3 monocytes (CD14+, top) and myeloid DCs (HLA-DR+CD11c+, bottom) producing IL-6, TNFɑ, or 4 both, following ex vivo stimulation with bacterial (left) and viral agonists ( (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2021. ; scRNA-Seq. (C) Bubble plot of identifying genes highly expressed in each cluster determined 1 using the FindMarkers function in Seurat. Level of normalized expression is shown using a color 2 scale ranging from low (blue) to high (red). Size of the bubble is representative of the fraction of 3 cells within each cluster expressing the marker. (D) Box plots comparing cell percentages 4 calculated from clusters identified by dimensional reduction of all scRNA-Seq data. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2021. ; (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2021.

The datasets supporting the conclusions of this article are available on NCBI's Sequence Read 2 Archive (SRA# pending). 3 4

Alpesh Amin reported serving as PI or co-I of clinical trials sponsored by NIH/NIAID, NeuroRx 6 Pharma, Pulmotect, Blade Therapeutics, Novartis, Takeda, Humanigen, Eli Lilly, PTC 7 Therapeutics, OctaPharma, Fulcrum Therapeutics, Alexion. He has served as speaker or 8 consultant for BMS, Pfizer, BI, Portola, Sunovion, Mylan/Theravance, Salix, Alexion, 9 AstraZeneca, Novartis, Nabriva, Paratek, Bayer, Tetraphase, Achogen LaJolla, Millenium, 10 Ferring, PeraHealth, HeartRite, Aseptiscope, Sprightly. We are grateful to all participants in this study. We thank Dr. Jennifer Atwood for assistance with 25 sorting and imaging flow cytometry in the flow cytometry core at the Institute for Immunology, UCI. 26

We thank Dr. Melanie Oakes from UCI Genomics and High-Throughput Facility for assistance 27 with 10X library preparation and sequencing. Aspects of experimental design figures were 28 generated using graphics from Biorender.com. We wish to acknowledge the support of the Chao 29

Family Comprehensive Cancer Center resources, supported by the National Cancer Institute of 30 the National Institutes of Health under award number P30CA062203. 31 32 33 34 35 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Regulator of Host Antiviral Responses. J Virol. 2019;93(21). 14 15

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2021. IL7R  CCL5  B2M  CFL1  CEBPB  HLA−DPA1  LGALS1  ISG20  IKZF1  IFIH1  IFIT3  IFI16  IRF7  STAT1  HLA−DPB1  IFIT1  OAS3  IFI44  IFI6  IFITM1  IFITM2  IFI44L  IFITM3  SOCS1  IFIT2  ISG15  PLCG2  IKZF3   TNFRSF18  STAT3  CXCR4  MAP3K8  HLA−E  TNF  CD44  IL4R  RELB  BCL3  HSPD1  CD83  TNFAIP3  ICAM1  SMAD3  RELA  GATA3  CD55  TNFSF14  APOBEC3G  LAG3  CD74  TNFRSF4  TNFRSF1B  PIK3R1  IFNGR1  IRF4  RUNX3  IL21R All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2021. 

Clinical Characteristics of Patients Who Died of 4

Coronavirus Disease 2019 in China

Estimation of 6 the asymptomatic ratio of novel coronavirus infections (COVID-19)

Transmission potential of the novel coronavirus (COVID-19) 9 onboard the diamond Princess Cruises Ship

Characteristics 11 and Outcomes of Patients 80 Years and Older Hospitalized With Coronavirus Disease 2019 12 (COVID-19)

Baseline 14 Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of 15 the Lombardy Region

Why does COVID-19 disproportionately affect 17 older people?

Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-20 analysis, and public policy implications

Clinical features of familial clustering 22 in patients infected with 2019 novel coronavirus in Wuhan, China

Clinical Characteristics of 138 24 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Hemodialysis Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Clin 28

Features 30 of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation 31 Protocol: prospective observational cohort study

Estimates of the 33 severity of coronavirus disease 2019: a model-based analysis

Clinical features of COVID-19 in elderly patients: A 36 comparison with young and middle-aged patients

Immunesenescence: A Predisposing Risk Factor for the 38 Development of COVID-19? Front Immunol

COVID-19 and 40 the elderly: insights into pathogenesis and clinical decision-making

How to Oppose Aging Strategically? A Review of 44 Potential Options for Therapeutic Intervention

Role of Aging and the Immune Response to 46

Respiratory Viral Infections: Potential Implications for COVID-19

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

A dynamic 4 COVID-19 immune signature includes associations with poor prognosis

Longitudinal 7 analyses reveal immunological misfiring in severe COVID-19

Immunology of COVID-9 19: Current State of the Science

An inflammatory cytokine signature predicts COVID-19 severity and survival

Complex Immune Dysregulation in COVID-19 Patients with Severe 15 Respiratory Failure

Comprehensive mapping of immune perturbations associated with severe COVID-19

Impaired type I 20 interferon activity and inflammatory responses in severe COVID-19 patients

Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment

26 Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19

A 29 single-cell atlas of the peripheral immune response in patients with severe COVID-19

Lymphopenia predicts 34 disease severity of COVID-19: a descriptive and predictive study

T cell responses in patients with COVID-19

Functional exhaustion of antiviral 39 lymphocytes in COVID-19 patients

Reduction and Functional 41 Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)

Impaired immune 44 cell cytotoxicity in severe COVID-19 is IL-6 dependent

Integrating single-cell 1 transcriptomic data across different conditions, technologies, and species

Massively 4 parallel digital transcriptional profiling of single cells

Slingshot: cell lineage and 6 pseudotime inference for single-cell transcriptomics

Metascape provides a biologist-oriented resource for the analysis of systems-level datasets

GM-CSF-based treatments in 17 COVID-19: reconciling opposing therapeutic approaches

Role of 19 CCL5 (RANTES) in viral lung disease

IP-10 and MCP-1 as biomarkers 21 associated with disease severity of COVID-19

Longitudinal COVID-19 profiling 23 associates IL-1RA and IL-10 with disease severity and RANTES with mild disease

Marked T 26 cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 27 pneumonia

Longitudinal 31 immune profiling reveals key myeloid signatures associated with COVID-19

Longitudinal Multi-34 omics Analyses Identify Responses of Megakaryocytes, Erythroid Cells, and Plasmablasts as 35 Hallmarks of Severe COVID-19

Dysregulated adaptive immune response 37 contributes to severe COVID-19

Expansion of myeloid-39 derived suppressor cells in patients with severe coronavirus disease (COVID-19). Cell Death 40 Differ

Deep 42 immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic 43 implications

T-Cell Hyperactivation and 45 Paralysis in Severe COVID-19 Infection Revealed by Single-Cell Analysis

Acute SARS-CoV-2 Infection 48 Impairs Dendritic Cell and T Cell Responses

Unique 50 immunological profile in patients with COVID-19